Citations

Clear

367 citation(s) found for "Benson, Al".

Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
Webb, Mason , Neth, Bryan J. , Webb, Lauren M. , Link, Michael J., Neff, Brian A., Carlson, Matthew L. , Driscoll, Colin L. W., Dornhoffer, Jim R., Ruff, Michael W. , Anderson, Kelsey A, Kizilbash, Sani H. , Campian, Jian , Uhm, Joon H. , Lane, Jack I, Blezek, Daniel J. , Mehta, P. , Sener, Uğur , Driscoll, Colin L., Dornhoffer, Jim, Benson, John C. , Mehta, Parv M, Sener, Ugur T, Neth, Byran J. , Kizilbash, Sani H , Sener, Ugur , Webb, Mason James , Mehta, Parv , Gompel, Jamie J. Van , Link, Michael J. , Lane, Jack I., Bathla, Girish

Mayo Clinic

Neuro-Oncology Advances | September 20, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad123 | PMID 37841698 Get It

Abstract Background Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant tumor-predisposition syndrome characterized by bilateral vestibular schwannomas (VS). In patients with VS associated with NF2, vascular endothelial growth factor A inhibitor, bevacizumab, is a systemic treatment option. The aim of this study is to retrospectively evaluate NF2 patient responses to bevacizumab on VS growth and symptom progression. Methods This is a retrospective analysis of patients seen at the Mayo Clinic Rochester Multidisciplinary NF2 Clinic. Results Out of 76 patients with NF2 evaluated between 2020 and 2022, we identified 19 that received treatment with bevacizumab. Thirteen of these patients discontinued bevacizumab after median treatment duration of 12.2 months. The remaining 6 patients are currently receiving bevacizumab treatment for a median duration of 9.4 months as of March, 2023. Fifteen patients had evaluable brain MRI data, which demonstrated partial responses in 5 patients, stable disease in 8, and progression in 2. Within 6 months of bevacizumab discontinuation, 5 patients had rebound growth of their VS greater than 20% from their previous tumor volume, while 3 did not. Three patients with rebound growth went on to have surgery or irradiation for VS management. Conclusions Our single-institution experience confirms prior studies that bevacizumab can control progression of VS and symptoms associated with VS growth. However, we note that there is the potential for rapid VS growth following bevacizumab discontinuation, for which we propose heightened surveillance imaging and symptom monitoring for at least 6 months upon stopping anti-VEGF therapy.
P11.16.B THE MAYO CLINIC MULTIDISCIPLINARY NF2 CLINIC EXPERIENCE OF BEVACIZUMAB IN NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS PATIENTS WITH VESTIBULAR SCHWANNOMAS
Webb, Lauren M. , Link, M J, Neff, Brian A., Carlson, Matthew L. , Driscoll, C W, Ruff, Michael W. , Anderson, Keith , Neth, Bryan J. , Kizilbash, Sani H. , Uhm, Joon H. , Lane, John I. , Blezek, Daniel J. , Mehta, P. , Neth, Byran J. , Kizilbash, Sani H , Mehta, Parv , Webb, Mason , Gompel, Jamie J. Van , Driscoll, Colin L. W., Anderson, K A, Benson, John C. , Bathla, Girish , Sener, Uğur

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii75-ii76

10.1093/neuonc/noad137.250 Get It

Abstract BACKGROUND Neurofibromatosis type 2-related schwannomatosis (NF2) is an autosomal dominant tumor-predisposition syndrome characterized by bilateral vestibular schwannomas (VS) as well as other nervous system tumors. Management decisions for NF2-related VS are typically predicated on tumor size, associated symptoms, patient age, and comorbidities. Observation, surgical resection, and stereotactic radiosurgery can be viable options. In patients with VS associated with NF2, vascular endothelial growth factor A (VEGF-A) inhibitor, bevacizumab, is a systemic treatment option. In this single institution study, we review our clinical experience in patients with NF2 who received bevacizumab for VS and evaluate the effect of bevacizumab treatment on VS growth and symptom progression. MATERIAL AND METHODS This is a retrospective analysis of patients seen at the Mayo Clinic Rochester Multidisciplinary NF2 Clinic. Three-dimensional volumetric data for VS were measured using manual segmentation with Visage PACS software under the direct supervision of a board-certified neuroradiologist. RESULTS Out of 76 patients with NF2 evaluated in the past 3 years, we identified 19 that received treatment with bevacizumab. Median age of NF2 diagnosis was 19 years (range 0.5-61) with a median NF2 phenotype severity score of 2 (range 1-3). Thirteen of these patients have discontinued bevacizumab, accounting for a median duration of 12.2 months (range 3.3-88 months) of bevacizumab treatment. Bevacizumab was discontinued due to hypertension (n=5), proteinuria and renal dysfunction (n=3), tumor progression (n=2), fatigue or other intolerance (n=2), or non-compliance (n=1). The remaining 6 patients are currently receiving bevacizumab treatment for a median duration of 9.4 months as of March 2023 (range 3.7-48.3 months). Fifteen patients had brain MRI data available to evaluate VS change during bevacizumab treatment, with partial response observed in 5 patients, stable disease in 8, and progression in 2. Ten of the 13 patients who stopped bevacizumab had MRI data to evaluate VS change following treatment termination. Within 6 months of bevacizumab discontinuation, 6 patients had rebound growth of their VS between 21-95% from their previous tumor volume, while 4 did not. Three patients with rebound growth went on to have surgery or irradiation for VS management. CONCLUSION Our single institution experience confirms that bevacizumab can slow progression of VS and symptoms associated with VS growth. However, we note that there is the potential for rapid VS growth following bevacizumab discontinuation, for which we propose heightened surveillance imaging and symptom monitoring for at least 6 months upon stopping anti-VEGF therapy.
Updated ultrafast dynamic computed tomography myelography technique for cerebrospinal fluid leaks
Mark, Ian T. , Madhavan, Ajay A. , Benson, John C. , Verdoorn, Jared T. , Yu, Lifeng , Benson, John , Mark, Ian , Madhavan, Ajay A , Yu, Lifeng

Mayo Clinic

Interventional Neuroradiology | August 22, 2023 | Volume: 32 | Issue: 3 | Pages: 1160-1163

10.1177/15910199231193463 | PMID 37606552 Get It

We present an updated ultrafast dynamic computed tomography myelography technique that can be used for the localization of spontaneous spinal cerebrospinal fluid leaks in the setting of spontaneous intracranial hypotension. This has over twice the temporal resolution of previously described techniques at the same radiation dose output.
Pituitary volume changes in pregnancy and the post-partum period
Benson, John C. , Malyuk, David F. , Madhavan, Ajay A. , Krecke, Karl N. , Little, Jason T. , Passe, Theodore J. , Lindell, E. Paul , Eckel, Laurence J. , Madhavan, Ajay A , DeLone, David R. , Lindell, Edward P, Benson, John , Guérin, J.

Mayo Clinic

The Neuroradiology Journal | August 17, 2023 | Volume: 37 | Issue: 1 | Pages: 39-42

10.1177/19714009231196470 | PMID 37590100 Get It

Purpose Imaging changes in the pituitary volume during pregnancy remains scantly researched. This study set out to assess the differences in total, anterior, and posterior pituitary volume in pregnant women compared to nulliparous and post-partum women. Materials and Methods A retrospective review was completed of women that had undergone MRI imaging of the brain. Patients were divided into three cohorts: pregnant, nulliparous, and post-partum (defined as being within 12 months of delivery). Anterior and posterior pituitary volumes were manually measured. Results 171 patients were included, of which 68 were pregnant, 52 were post-partum, and 51 were nulliparous. The average anterior (621.0 ± 171.6 mm 3 ) and total (705.4 ± 172.2 mm 3 ) pituitary volumes were significantly larger in pregnant patients than nulliparous women (522.6 ± 159.8 mm 3 and 624.5 ± 163.7 mm 3 , respectively) ( p = .002 and p = .01, respectively). The posterior pituitary volume was significantly smaller in pregnant women (84.4 ± 32.9 mm 3 ) compared to both post-partum (101.2 ± 42.0 mm 3 ) and nulliparous (102.0 ± 46.1 mm 3 ) women ( p = .02 for both). Conclusions The anterior and total pituitary volumes are significantly larger during pregnancy persisting into the post-partum period. The posterior pituitary volume, conversely, decreases during pregnancy, and returns to its normal size in the post-partum period.
Magnetic Resonance Imaging Artifact Associated With Transcutaneous Bone Conduction Implants: Cholesteatoma and Vestibular Schwannoma Surveillance
Nassiri, Ashley M. , Lane, John I. , McGee, Kiaran P. , Trzasko, Joshua D. , Carlson, Matthew L. , Messina, Steven A. , Benson, John C.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 16, 2023 | Volume: 170 | Issue: 1 | Pages: 187-194

10.1002/ohn.474 | PMID 37582349 Get It

AbstractObjectiveTo evaluate the magnetic resonance (MR) image artifact and image distortion associated with the two transcutaneous bone conduction implants currently available in the United States.Study DesignCadaveric study.MethodsTwo cadaveric head specimens (1 male, 1 female) were unilaterally implanted according to manufacturer guidelines and underwent MR imaging (General Electric and Siemens 1.5 T scanners) under the following device conditions: (1) no device, (2) Cochlear Osia with magnet and headwrap, (3) Cochlear Osia without magnet, and (4) MED‐EL Bonebridge with magnet. Maximum metal mitigation techniques were employed in all conditions, and identical sequences were obtained. Blinded image scoring (diagnostic vs nondiagnostic image) was performed by experienced neuroradiologists according to anatomical subsites.ResultsAll device conditions produced artifact and image distortion. The Osia with magnet produced diagnostic T1‐ and T2‐weighted images of the ipsilateral temporal bone, however, non‐echo planar imaging diffusion‐weighted imaging (DWI) was nondiagnostic. The Osia without magnet scanned on the Siemens MR imaging demonstrated the least amount of artifact and was the only condition that allowed for diagnostic imaging of the ipsilateral temporal bone on DWI. The Bonebridge produced a large area of artifact and distortion with the involvement of the ipsilateral and contralateral temporal bones.ConclusionIn summary, of the three device conditions (Osia with magnet, Osia without magnet, and Bonebridge), Osia without magnet offered the least amount of artifact and distortion and was the only condition in which diagnostic DWI was available for the middle ear and mastoid regions on the Siemens MR imaging scanner.
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, Bruce J. , Catalano, Paul J. , Meropol, Neal J. , O’Dwyer, Peter J. , Mitchell, Edith P. , Schwartz, Michael , Benson, Al B. , Schwartz, Michael A , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | July 17, 2023 | Volume: 41 | Issue: 21 | Pages: 3670-3675

10.1200/jco.22.02761 | PMID 37459754 Get It

Purpose Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. Patients and Methods Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. Results The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively ( P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. Conclusion The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. Gabriela , Chiaro, Marco Del , Tempero, Margaret A. , Malafa, Mokenge P. , Benson, Al B. , Cardin, Dana B. , Christensen, Jared A. , Czito, Brian G. , Dillhoff, Mary , Donahue, Timothy R. , Hardacre, Jeffrey M., Klute, Kelsey , Ko, Andrew H. , LoConte, Noelle K. , Lowy, Andrew M. , Masood, Ashiq , Moravek, Cassadie, Nakakura, Eric K. , Narang, Amol , Nardo, Lorenzo , Obando, Jorge, Reddy, Sushanth , Reyngold, Marsha , Scaife, Courtney L. , Shen, Jeanne , Truty, Mark J. , Vollmer, Charles M., Wolff, Robert A. , Wolpin, Brian M. , McCullough, Beth, Lubin, Senem, Darlow, Susan, Cardin, Dana B , LoConte, Noelle , Chung, Vincent , Dotan, Efrat , Fountzilas, Christos , Glazer, Evan S. , Hawkins, William G , Kunstman, John W. , Polanco, Patricio Marcelo

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 753-782

10.6004/jnccn.2023.0034 | PMID 37433437 Get It

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Benson, Al B. , D’Angelica, Michael I. , Abbott, Daniel E. , Ahmed, Aijaz, Anaya, Daniel A. , Are, Chandrakanth , Binder, David C. , Bowlus, Christopher L. , Burgoyne, Adam M. , Castellanos, Jason , Chahal, Prabhleen , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Jennings, Lawrence J. , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Reddy, Sanjay S. , Sahai, Vaibhav , Singh, Gagandeep , Stein, Stacey , Yopp, Adam C. , McMillian, Nicole R., Schonfeld, Ryan, Hochstetler, Cindy, Bowlus, Christopher L , Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Borad, Mitesh J. , Brown, Daniel B. , Glazer, Evan S. , Hawkins, William G , Levine, Matthew H , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 694-704

10.6004/jnccn.2023.0035 | PMID 37433432 Get It

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.
Prevalence of intra-osseous veins and venous lakes in the posterior skull base on 3T MRI
Benson, John C. , Hamilton-Cave, Matt, Lane, John I. , Benson, John , Hamilton-Cave, Matthew A., Carr, Carrie M.

Mayo Clinic

The Neuroradiology Journal | June 29, 2023 | Volume: 36 | Issue: 6 | Pages: 702-706

10.1177/19714009231187350 | PMID 37382936 Get It

Background Intra-osseous vessels are normal anatomic structures in the calvarium and skull base. On imaging, these structures—particularly venous lakes—can mimic pathologic abnormalities. This study sought to assess the prevalence of veins and lakes in the skull base on MRI. Materials and Methods A retrospective review was completed of consecutive patients that underwent contrast-enhanced MRI imaging of the internal auditory canals. The clivus, jugular tubercles, and basio-occiput were assessed for the presence of both intra-osseous veins (serpentine and/or branching vessels) and venous lakes (well-circumscribed round or oval enhancing structures). Vessels in the adjacent synchondroses major foramina were excluded. Three board-certified neuroradiologists performed independent blinded reviews, with discrepancies agreed upon by consensus. Results 96 patients were included in this cohort (58.3% female). Mean age was 58.4 years (range = 19–85). At least one intra-osseous vessel was identified in 71 (74.0%) patients. 67 (70.0%) had at least one skull base vein, and 14 (14.6%) had at least one venous lake. Both vessel subtypes were observed in 8.3% of patients. Vessels were more commonly observed in women, though this did not reach statistical threshold ( p = 0.56). Age was not associated with the presence of vessels (0.59) or vessel location ( p values ranged from 0.44–0.84). Conclusions Intra-osseous skull base veins and venous lakes are relatively common findings on MRI. Both vascular structures should be considered normal anatomy, and care should be taken to not confuse these for pathologic entities.
Complications Occurring Through 5 Years Following Primary Intraocular Lens Implantation for Pediatric Cataract
Yen, Kimberly G., Repka, Michael X. , Sutherland, Desirae R. , Haider, Kathryn M. , Kraker, Raymond T. , Galvin, Jennifer, Li, Zhuokai , Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Astle, William F., Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Bothun, Erick D. , Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Hatt, Sarah R. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Freedman, Sharon F. , Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Wu, Rui , Saunders, Richard Anthony , Salchow, Daniel J. , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | June 23, 2023 | Volume: 141 | Issue: 8 | Pages: 705

10.1001/jamaophthalmol.2023.2335 | PMID 37347490 Get It

Importance Lensectomy with primary intraocular lens (IOL) implantation is often used in the management of nontraumatic pediatric cataract, but long-term data evaluating the association of age and IOL location with the incidence of complications are limited. Objective To describe the incidence of complications and additional eye surgeries through 5 years following pediatric lensectomy with primary IOL implantation and association with age at surgery and IOL location. Design, Setting, and Participants This prospective cohort study used Pediatric Eye Disease Investigator Group cataract registry data from 61 institution- and community-based practices over 3 years (June 2012 to July 2015). Participants were children younger than 13 years without baseline glaucoma who had primary IOL implantation (345 bilateral and 264 unilateral) for nontraumatic cataract. Data analysis was performed between September 2021 and January 2023. Exposures Lensectomy with primary IOL implantation. Main Outcome and Measures Five-year cumulative incidence of complications by age at surgery (&amp;lt;2 years, 2 to &amp;lt;4 years, 4 to &amp;lt;7 years, and 7 to &amp;lt;13 years) and by IOL location (sulcus vs capsular bag) were estimated using Cox proportional hazards models. Results The cohort included 609 eyes from 491 children (mean [SD] age, 5.6 [3.3] years; 261 [53%] male and 230 [47%] female). Following cataract extraction with primary IOL implantation, a frequent complication was surgery for visual axis opacification (VAO) (cumulative incidence, 32%; 95% CI, 27%-36%). Cumulative incidence was lower with anterior vitrectomy at the time of IOL placement (12%; 95% CI, 8%-16%) vs without (58%; 95% CI, 50%-65%), and the risk of undergoing surgery for VAO was associated with not performing anterior vitrectomy (hazard ratio [HR], 6.19; 95% CI, 3.70-10.34; P &amp;lt; .001). After adjusting for anterior vitrectomy at lens surgery, there were no differences in incidence of surgery for VAO by age at surgery (&amp;lt;2 years, HR, 1.35 [95% CI, 0.63-2.87], 2 to &amp;lt;4 years, HR, 0.86 [95% CI, 0.44-1.68], 4 to &amp;lt;7 years, HR, 1.06 [95% CI, 0.72-1.56]; P = .74) or by capsular bag vs sulcus IOL fixation (HR, 1.22; 95% CI, 0.36-4.17; P = .75). Cumulative incidence of glaucoma plus glaucoma suspect by 5 years was 7% (95% CI, 4%-9%), which did not differ by age after controlling for IOL location and laterality. Conclusions and Relevance In this cohort study, a frequent complication following pediatric lensectomy with primary IOL was surgery for VAO, which was associated with primary anterior vitrectomy not being performed but was not associated with age at surgery or IOL location. The risk of glaucoma development across all ages at surgery suggests a need for long-term monitoring.